Prognostic impact of a lymphocyte activation-associated gene signature in GBM based on transcriptome analysis.

Citation metadata

Date: Aug. 25, 2021
From: PeerJ(Vol. 9)
Publisher: PeerJ. Ltd.
Document Type: Article
Length: 5,976 words
Lexile Measure: 1320L

Document controls

Main content

Abstract :

Background Glioblastoma multiforme (GBM) is a highly, malignant tumor of the primary central nervous system. Patients diagnosed with this type of tumor have a poor prognosis. Lymphocyte activation plays important roles in the development of cancers and its therapeutic treatments. Objective We sought to identify an efficient lymphocyte activation-associated gene signature that could predict the progression and prognosis of GBM. Methods We used univariate Cox proportional hazards regression and stepwise regression algorithm to develop a lymphocyte activation-associated gene signature in the training dataset (TCGA, n=525). Then, the signature was validated in two datasets, including GSE16011 (n=150) and GSE13041 (n=191) using the Kaplan Meier method. Univariate and multivariate Cox proportional hazards regression models were used to adjust for clinicopathological factors. Results We identified a lymphocyte activation-associated gene signature (TCF3, IGFBP2, TYRO3 and NOD2) in the training dataset and classified the patients into high-risk and low-risk groups with significant differences in overall survival (median survival 15.33 months vs 12.57 months, HR = 1.55, 95% CI [1.28-1.87], log-rank test P Conclusions In summary, our results suggested that the lymphocyte activation-associated gene signature is a promising factor for the survival of patients, which is helpful for the prognosis of GBM patients.

Source Citation

Source Citation   

Gale Document Number: GALE|A673122559